Literature DB >> 23280748

Probing AGXT2 enzyme activity in mouse tissue by applying stable isotope-labeled asymmetric dimethyl arginine as substrate.

Jens Martens-Lobenhoffer1, Roman N Rodionov, Stefanie M Bode-Böger.   

Abstract

Asymmetric dimethylarginine (ADMA) is a metabolite of the amino acid L-arginine. It competitively inhibits the enzymatic production of the cell-signaling substance nitric oxide. Therefore, increased levels of ADMA are associated with a range of cardiovascular and other diseases. ADMA is biologically eliminated by direct renal excretion and hydrolysis by the enzyme DDAH. Recently, a further elimination pathway via the transamination by the enzyme AGXT2 to α-keto-δ-(N(G),N(G)-dimethylguanidino)valeric acid (DMGV) has come into the focus of biological research. In this work, we describe an assay for the AGXT2 activity in mouse liver and kidney tissue. It is based on the transformation of isotope-labeled ADMA-d(6) to DMGV-d(6). The quantification of the DMGV-d(6) produced by this reaction in tissue homogenate samples was accomplished by chromatographic separation on a porous graphitic carbon column and tandem mass spectrometric detection. DMGV-d(6) with the deuterium labels in different molecular positions was used as internal standard. The overall production rates of DMGV-d(6) in mice were 195.37 pmol/min/mg total protein in liver and 85.21 pmol/min/mg total protein in kidney tissue, with coefficients of variation of 6.31% and 11.25%, respectively. This method can be applied as a tool for the characterization of the ADMA elimination by the AGXT2 pathway.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23280748     DOI: 10.1002/jms.3125

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  5 in total

1.  Association of Dimethylguanidino Valeric Acid With Partial Resistance to Metabolic Health Benefits of Regular Exercise.

Authors:  Jeremy M Robbins; Matthew Herzig; Jordan Morningstar; Mark A Sarzynski; Daniel E Cruz; Thomas J Wang; Yan Gao; James G Wilson; Claude Bouchard; Tuomo Rankinen; Robert E Gerszten
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

Review 2.  AGXT2: a promiscuous aminotransferase.

Authors:  Roman N Rodionov; Natalia Jarzebska; Norbert Weiss; Steven R Lentz
Journal:  Trends Pharmacol Sci       Date:  2014-10-13       Impact factor: 14.819

3.  Effects of AGXT2 variants on blood pressure and blood sugar among 750 older Japanese subjects recruited by the complete enumeration survey method.

Authors:  Yuta Yoshino; Hiroshi Kumon; Takaaki Mori; Taku Yoshida; Ayumi Tachibana; Hideaki Shimizu; Jun-Ichi Iga; Shu-Ichi Ueno
Journal:  BMC Genomics       Date:  2021-04-20       Impact factor: 3.969

4.  DMGV Is a Rheostat of T Cell Survival and a Potential Therapeutic for Inflammatory Diseases and Cancers.

Authors:  Fengyuan Mandy Yang; Liya Shen; Dengxia Denise Fan; Kuan-Hung Chen; Jongdae Lee
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

5.  Diabetes-linked transcription factor HNF4α regulates metabolism of endogenous methylarginines and β-aminoisobutyric acid by controlling expression of alanine-glyoxylate aminotransferase 2.

Authors:  Dmitry V Burdin; Alexey A Kolobov; Chad Brocker; Alexey A Soshnev; Nikolay Samusik; Anton V Demyanov; Silke Brilloff; Natalia Jarzebska; Jens Martens-Lobenhoffer; Maren Mieth; Renke Maas; Stefan R Bornstein; Stefanie M Bode-Böger; Frank Gonzalez; Norbert Weiss; Roman N Rodionov
Journal:  Sci Rep       Date:  2016-10-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.